It improves the effectiveness of BRAF inhibitors, such as dabrafenib, but increases the risk of pulmonary embolism at least 4-fold compared to BRAF monotherapy, as seen in a systematic review and meta-analysis [96]. Here, BRAF is linked to pulmonary embolism.